In summary, we comprehensively demonstrated the immune landscape of NSCLC through MIF analysis and further identified three robust immune subtypes, which may help identify the ideal candidates and tailor rational immunotherapeutic strategies. The gene discussed is MIF; the disease is non-small cell lung carcinoma.